Replies to post #244871 on Biotech Values

[DewDiligence]

The FDA-AMRN lawsuit settlement involved promotion for off-label indications. What we’re discussing vis-à-vis RVNC is the more limited question of a drugmaker’s using published clinical data in its promotion.

This NEJM article from 2009 is on-topic:
https://www.nejm.org/doi/10.1056/NEJMhle0807695